Key facts
- This page summarizes Jeffrey Chi's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Feb 2025, 16:57.
Jeffrey Chi - 14 Feb 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)
- Reporting relationship
- Director
- Issuer ticker
- AARD
- Reported as of
- 14 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 16:57:41 UTC
- Prior SEC filing
- 12 Feb 2025
- Next SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Chi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey Chi filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 12 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AARD
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +133,364
- Change %
- Price
- Shares after
- 133,364
- Date
- 14 Feb 2025
- Ownership
- By Vickers Venture Co-investment LLC
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AARD
transaction
Derivative
Series C Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,130,135
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 14 Feb 2025
- Ownership
- By Vickers Venture Co-investment LLC
- Underlying class
- Common Stock
- Underlying amount
- 133,364
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.
Footnote F2
Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.